TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2024 European Society of Medical Oncology Congress ...Middle East

TORL-1-23 Demonstrates Clinically Meaningful, Durable and Confirmed Responses with a Generally Manageable Safety Profile in Patients with Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian Cancer Expansion Cohorts in Patients with Ovarian, Non-Small Cell Lung Cancer, and Other CLDN6+...

Hence then, the article about torl biotherapeutics presents updated phase 1 results of novel claudin 6 targeted antibody drug conjugate torl 1 23 at the 2024 european society of medical oncology congress was published today ( Sunday 15/09/2024 - 10:16 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2024 European Society of Medical Oncology Congress )

Also on site :

• Clarivate Selected By Czech National Library of Technology to Develop Unified National Library Platform
• Jell-O Just Introduced a Modern New Dessert Line—and It’s Here To Stay
• FIFA’s empire of double standards: Why the 2026 World Cup is already a disaster